Development, Commercialization and Supply Agreements (Tables)

9 Months Ended

Sep. 30, 2024

License And Collaboration Agreements [Line Items]

Summary of Licensing Revenue

In thousands	Amount
Licensing revenue recognized during the nine months ended September 30, 2024 (1)	$	19,426
Licensing revenue recognized during the nine months ended September 30, 2023 (1)		9,400
Licensing revenue recognized from contract inception through September 30, 2024		40,081
Licensing revenue recognized from contract inception through December 31, 2023	$	20,655

(1)Licensing revenue under the DCS Agreement is recognized concurrent with the input measure of support hours provided by Amarin to Edding in achieving the combined development and regulatory performance obligation, which in the Company’s judgment is the best measure of progress towards satisfying this performance obligation.

Summary of Product Approval

The Company received approval of VASCEPA under the MARINE and REDUCE-IT indications in the following countries:

Country	MARINE	REDUCE-IT	Launch Date
Lebanon	March 2018	August 2021	June 2018
United Arab Emirates	July 2018	October 2021	February 2019
Qatar	December 2019	April 2021	N/A
Bahrain	April 2021	April 2022	N/A
Kuwait	December 2021	March 2023	September 2023
Saudi Arabia	March 2022	June 2023	September 2023

Changes in Balances of Contract Assets and Liabilities and Revenues Recognized

The following table presents changes in the balances of the Company’s contract assets and liabilities during the nine months ended September 30, 2024 and 2023:

In thousands	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Nine months ended September 30, 2024:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue 1	$	4,850	$	—	$	(4,850	)	$	—
Nine months ended September 30, 2023:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue 2	$	15,346	$	5,000	$	(15,372	)	$	4,974

(1)The approximately $4.9 million reduction consists primarily of recognition of $4.0 million relating to the change in estimate for Edding during the three months ended June 30, 2024.

(2)The approximately $15.0 million reduction consists of recognition of $5.0 million and $5.3 million relating to the change in estimate for Edding and HLS, respectively, as well as recognizing, based on the revised timeline, $3.9 million for the MARINE indication approval in China achieved during the three months ended June 30, 2023.

During the nine months ended September 30, 2024 and 2023, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods:

In thousands	Nine months ended September 30,
Revenue recognized in the period from:	2024		2023
Amounts included in contract liability at the beginning of the period	$	1,180	$	11,479
Performance obligations satisfied in previous periods	$	3,670	$	1,722

Edding

License And Collaboration Agreements [Line Items]

Summary of Transaction Price Comprising Upfront Payments and Milestones

The transaction price is comprised of the following upfront payments and milestones:

In thousands
Transaction Price Components	Achieved	Amount
Upfront fee	February 2015	$	15,000
Submission of the CTA for the MARINE indication	March 2016		1,000
Approval of VASCEPA under the MARINE indication	March 2017		5,000
Submission of the CTA for the REDUCE-IT indication	October 2023		3,000
Approval of VASCEPA under the REDUCE-IT indication	June 2024		15,000
Regulatory Development Support	Various		1,081
Total Transaction Price		$	40,081

HLS

License And Collaboration Agreements [Line Items]

Summary of Transaction Price Comprising Upfront Payments and Milestones

The transaction price is comprised of the following upfront payments and milestones:

In thousands
Transaction Price Components	Achieved	Amount
Upfront fee	September 2017	$	5,000
Achievement of the REDUCE-IT trial primary endpoint	September 2018		2,500
Approval from Health Canada	December 2019		2,500
Regulatory exclusivity from the Office of Patented Medicines and Liaison	January 2020		3,800
Total Transaction Price		$	13,800